Antimicrobial resistance is one of the greatest global health challenges of our time. At ICON, we are committed to advancing research to find solutions that protect patients and preserve the effectiveness of life-saving treatments. FIRECREST has supported more than 110 infectious disease trials. Watch our latest medical animation to understand how antimicrobial resistance develops and why collaboration across healthcare, research, and communities is critical. Discover more: https://ow.ly/YohO50XsxYE #WAAW #AntimicrobialResistance
About us
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
External link for ICON plc
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Dublin
- Type
- Public Company
- Specialties
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs, and Global Patient Insights & Engagement
Locations
Employees at ICON plc
Updates
-
Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists. If you are interested in coming along on the 4th December please register here: https://ow.ly/SUrV50XuHJx
-
-
As we mark World Antimicrobial Awareness Week, it’s time to spotlight innovative solutions to AMR. ICON’s article examines bacteriophage therapy and its potential to fight multidrug-resistant infections. Learn more: https://ow.ly/s2F150XnHHA
-
-
As you plan your remaining 2025 budget, consider unlocking the power of Social Determinants of Health (SDoH) for smarter strategies that can transform your approach. Symphony Health, an ICON plc company’s SDoH dataset adds critical social, economic, and environmental context to patient-level data—helping you understand the “why” behind patient behaviour. From improving adherence to advancing health equity, SDoH insights make strategies more precise and impactful, with Symphony offering fast-turn delivery and flexible licensing options. Explore how SDOH can support your Q4 goals and 2026 planning: https://ow.ly/gV8450Xsz3E #PharmaData, #HealthcareAnalytics, #RealWorldData, #PatientInsights, #SDOH, #SocialDeterminantsOfHealth, #HealthEquity, #PopulationHealth, #Q4Planning, #2026Strategy, #HealthcareMarketing
-
-
Approximately 11% of sites failing to recruit a single patient. Visit us at #ASH25, booth #2161 to learn about One Search, ICON’s award winning, AI-driven site selection tool to help identify the right sites the first time. https://ow.ly/PuyR50XkiX2
-
-
Unlock market access insights before year-end. As you plan your remaining 2025 budget, consider a strategic investment: payer analytics from Symphony Health, an ICON plc company. Our solutions help you understand how coverage decisions, benefit design, and formulary controls impact patient access — and how to respond effectively. Key offerings include: • Payer Landscape Reports – Competitive access insights across plans and geographies • True Benefit Design – Analyse benefit structures and patient behaviour • Plan Control Indices – Quantify prior auth and step edit impact • Medicare Part D / LIS Analytics – Support affordability strategies No additional data costs for existing patient data deliverables - making this a fast-turn, high-impact investment for Q4 and 2026 planning. Learn more: https://ow.ly/tmKH50XsyTj #MarketAccess #PayerAnalytics #FormularyManagement #BenefitDesign #HealthcareAnalytics #MedicarePartD #Q4Planning #2026Strategy #HealthcareInnovation
-
-
This year’s theme for World Children’s Day is "Listen to the future, stand up for children's rights”. ICON is invested in bringing safe, effective, pediatric-tested treatments to children all over the world. In the past 5 years, ICON has participated in 420+ clinical studies involving pediatric patients, enrolling 227,600+ patients at 19,200+ sites. Learn more: https://ow.ly/2b5o50Xqptr #WorldChildrensDay #ChildrensRights
-
-
PubsHub Journals & Congresses includes built-in screening to help safeguard authors from predatory journals and congresses. With rigorous checks and trusted data, the system helps ensure your work is submitted to credible, reputable venues. Make smarter, safer publishing decisions. Request a demo to see how it works. https://ow.ly/exjF50XaS2Q
-
-
In recognition of World Children’s Day, ICON’s Patient Centred Outcomes (PCO) team proudly reaffirms its commitment to improving the lives of children and families facing complex health challenges. Our dedicated team of over 45 experts across Europe and North America works to ensure that the voices of children, caregivers, and families are central to clinical development and healthcare decision-making. By understanding the physical, emotional, and social impact of pediatric conditions, we help shape research that truly reflects patient needs. Below are some of PCO’s key publications highlighting the depth and impact of patient and caregiver contributions to pediatric research: - Burden of treatments for respiratory complications in extremely premature infants: Interviews with caregivers: https://ow.ly/hAiM50Xqphp - Development of the PREMature Infant Index (PREMII™), a clinician-reported outcome measure assessing functional status of extremely preterm infants: https://ow.ly/zpWJ50Xqpho - Development of a severity scale to assess chronic lung disease after extremely preterm birth: https://ow.ly/Zzbh50Xqphn #WorldChildrensDay #ChildrensRights
-
-
For the second article in our new series, we delve deeper into ISO 14971 (Application of risk management to medical devices). We discuss a history of risk-based thinking and common misunderstandings around risk analysis methods. Ultimately, ISO 14971 provides a framework, but it is up to the user to fill it with analyses and evaluations that are fit for purpose and sufficient for regulatory conformity. Learn more https://ow.ly/J8wK50XlJpo #regulatoryaffairs #MDR #medicaldevices #MedTech #ISO #MedSafety
-